For the quarter ending 2026-03-31, PRLD made $4,580K in revenue. -$10,434K in net income. Net profit margin of -227.82%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 4,580 | 5,640 | 6,500 | - |
| Research and development | 13,601 | 17,992 | 21,708 | 25,784 |
| General and administrative | 5,156 | 4,996 | 5,210 | 6,410 |
| Total operating expenses | 18,757 | 22,988 | 26,918 | 32,194 |
| Loss from operations | -14,177 | -17,348 | -20,418 | -32,194 |
| Other income, net | 3,792 | 891 | 693 | 963 |
| Net loss | -10,385 | -16,457 | -19,725 | -31,231 |
| Unrealized gain on marketable securities, net of tax | -49 | 6 | 3 | -13 |
| Comprehensive loss | -10,434 | -16,451 | -19,722 | -31,244 |
| Basic EPS | -0.13 | -0.206 | -0.26 | -0.41 |
| Diluted EPS | -0.13 | -0.206 | -0.26 | -0.41 |
| Basic Average Shares | 82,519,981 | 79,712,217 | 76,132,337 | 75,993,941 |
| Diluted Average Shares | 82,519,981 | 79,712,217 | 76,132,337 | 75,993,941 |
Prelude Therapeutics Inc (PRLD)
Prelude Therapeutics Inc (PRLD)